We present a case of papillary thyroid cancer (post-thyroidectomy status) on regular treatment with suppressive Levothyroxine therapy. On follow-up at 6 months after radioactive iodine ablation for remnant thyroid tissue, her thyroglobulin, and antithyroglobulin levels were 0.06 ng/ml and 670 IU/ml, respectively. Low-dose whole-body I-131 scan was negative. To look for the cause of isolated increased anti-thyroglobulin level, a whole-body 18 F-FDG PET/CT was done which revealed multiple FDG-avid lytic skeletal lesions suggestive of metastases. For confirmation of diagnosis, 18 F-FDG PET/CT-guided metabolic biopsy was done, which revealed Langerhans' cell histiocytosis on histopathological examination.
Forty-five-year-old female with left thyroid swelling (~5 cm) underwent total thyroidectomy and nodal exploration. Histopathology revealed papillary thyroid cancer (PTC) with no nodal involvement (classical variant, T3pNoMo). Post-therapy scan (a, b) acquired after 72 h of 50 mCi of I-131 iodine administration revealed remnant thyroid tissue in the thyroid bed. She was kept on follow-up with suppressive dose of levothyroxine therapy. On follow-up visit at 6 months, after levothyroxine withdrawal (serum TSH level 119 mIU/l), she had thyroglobulin level of 0.06 ng/ml but elevated anti-thyroglobulin antibody (antiTg Ab) titer (670 IU/ml; normal < 116) and a negative low-dose whole-body I-131 scan (c, d). . PTC accounts for more than 85 to 90% of all thyroid malignancies [2, 3] . It is seen more commonly in females between 3rd to 5th decades. At initial diagnosis, 1-3% has distant metastases while 7-23% will develop distant metastases during the follow-up period [4] [5] [6] [7] . Although, the distant metastases are quite uncommon in PTC, but lung and bone are the most common sites [8] . The BRAF V600E mutation is most common genetic mutation detected in patients with PTC and occurs in approximately 45% of patients [9] . BRAF V600E mutation is also found to be associated with LCH in~50% of patients [10] . LCH in adults is a rare disorder occurring in 1-2 adults per million people with male predominance (2:1). It involves the bone, lung, skin, lymph nodes, and multiple sites and very rarely thyroid. Coexistence of LCH and PTC has been described in a few isolated case reports only; however, its significance is still unknown [11, 12] . LCH of the thyroid can both masquerade as a malignancy or coexist with other thyroid neoplasm because of the sharing of some common cytomorphologic features such as grooved nuclei, with PTC, which makes the pathological diagnosis even more difficult and may have increased anti-Tg Ab levels [13, 14] . The present case highlights the need of histopathology for distant skeletal lesions with increased anti-Tg Ab titer and negative iodine scintigraphy in PTC patients
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